Northland Capital partners view on Immupharma PLC: Mauritius has a high proportion of Lupus sufferers. The Mauritian Government’s strong interest in Lupuzor™ demonstrates how Lupus is an unmet medical need for which an effective therapy is highly sought after.
ImmuPharma (IMM.L) – BUY*: Update on Phase 3 trial |
Market Cap: £42m; Current Price: 34p; Target Price: 171p |
Additional site in Mauritius |
n ImmuPharma issued an update on the progress of its Phase 3 clinical trial of Lupuzor™, its lead programme for the potential treatment of Lupus.
n At the request of the Mauritian Government, ImmuPharma will open a new site in Mauritius to participate in the current pivotal Phase 3 trial. n It is anticipated that around 30 Lupus patients will commence recruitment within this new site over the next few weeks as part of the ongoing 200 patient Lupuzor™ trial. n Mauritius, with a population of around 1.2 million, is prevalent to a high proportion of Lupus sufferers, with approximately 3000 current Lupus patients. |